SEC Form 4 · accession 0001209191-18-058647
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Officer — Chief Executive Officer · Director
Period of report
Nov 9, 2018
Accepted (ET)
Nov 14, 2018 · 8:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 9, 2018 | A | 18,500 | $0.00 | A | 264,383 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On July 1, 2015, the reporting person was granted performance restricted stock units (PRSUs) covering 37,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner.